Bone Disease

Bisphosphonates are pyrophosphate analogs most well-known for treating osteoporosis by preventing bone loss. Bisphosphonates end in the suffix “-dronate” or “-dronic acid" (e.g., alendronate, risedronate, pamidronate) and bind to hydroxyapatite crystals in bone, inhibiting osteoclast-induced bone resorption. Bisphosphonates are indicated for postmenopausal osteoporosis, glucocorticoid-induced osteopenia/osteoporosis, and Paget disease of the bone. Adverse effects include hypocalcemia, hypophosphatemia, avascular necrosis of the femur, and osteonecrosis of the jaw. Contraindications include hypersensitivity reactions and esophageal disorders. Bisphosphonates may interact with aminoglycosides, aspirin, and proton pump inhibitors.

Hormones are messenger molecules that are synthesized in one part of the body and move through the bloodstream to exert specific regulatory effects on another part of the body. Hormones play critical roles in coordinating cellular activities throughout the body in response to the constant changes in both the internal and external environments. The work of hormones allows the body to maintain homeostasis and regulate growth and development. Hormones are typically either made from amino acids or derived from cholesterol (the latter group being known as steroid hormones). Hormones exert their effects by binding to receptors either on the cell surface (most amino acid–based hormones) or within the cytosol (steroid hormones). Ultimately, binding to receptors triggers changes in gene expression or enzymatic activity within the cell.

Osteoporosis refers to a decrease in bone mass and density leading to an increased number of fractures. There are 2 forms of osteoporosis: primary, which is commonly postmenopausal or senile; and secondary, which is a manifestation of immobilization, underlying medical disorders, or long-term use of certain medications. Osteoporosis most often presents clinically with frequent fractures and loss of vertebral height. Diagnosis is established by measuring bone mineral density. Management includes lifestyle modifications, maintaining adequate levels of calcium and vitamin D, and the use of bisphosphonates.

Paget's disease of bone (PDB), also known historically as osteitis deformans, is a focal disorder of bone metabolism that affects about 2%–9% of people. Commonly affected areas include the skull, spine, pelvis, and long bones of the lower extremity. The 2 main clinical manifestations of Paget's disease are bone pain and the consequences of bone deformities, such as fractures, osteoarthritis, or nerve impingement. The management includes bisphosphonates, calcitonin, and surgery for the management of fractures, deformities, and complications. The prognosis for PDB is good, especially if treatment is started before major changes have occurred in the bones.